QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
NASDAQ:EQ

Equillium (EQ) Stock Price, News & Analysis

$1.77
-0.08 (-4.32%)
(As of 05:27 PM ET)
Today's Range
$1.72
$1.90
50-Day Range
$0.80
$3.00
52-Week Range
$0.45
$3.25
Volume
85,943 shs
Average Volume
340,263 shs
Market Capitalization
$62.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.90

Equillium MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
120.3% Upside
$3.90 Price Target
Short Interest
Healthy
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.08) to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.75 out of 5 stars

Medical Sector

663rd out of 928 stocks

Pharmaceutical Preparations Industry

307th out of 434 stocks

EQ stock logo

About Equillium Stock (NASDAQ:EQ)

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

EQ Stock Price History

EQ Stock News Headlines

Elon’s Secret A.I. Supplier… REVEALED
After revolutionizing online payment processing (PayPal), space exploration (SpaceX) and the auto industry (Tesla)... He’s getting ready to do it again with his new A.I. venture. This could be bigger than Tesla, bigger than SpaceX, and bigger than Paypal.
Equillium Shares Fall After Swing to 4Q Loss
Elon’s Secret A.I. Supplier… REVEALED
After revolutionizing online payment processing (PayPal), space exploration (SpaceX) and the auto industry (Tesla)... He’s getting ready to do it again with his new A.I. venture. This could be bigger than Tesla, bigger than SpaceX, and bigger than Paypal.
Equillium: Q4 Earnings Insights
ROOT Sep 2024 7.500 put
SMCI Mar 2024 970.000 call
SMCI Mar 2024 765.000 call
SMCI Mar 2024 800.000 put
SMCI Feb 2024 1460.000 put
SMCI Mar 2024 695.000 put
Equillium Stock (NASDAQ:EQ), Short Interest Report
EQ Bank Card launches in Québec as Carte Banque EQ
See More Headlines
Receive EQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/15/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.90
High Stock Price Target
$5.00
Low Stock Price Target
$2.80
Potential Upside/Downside
+120.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,340,000.00
Pretax Margin
-35.35%

Debt

Sales & Book Value

Annual Sales
$36.08 million
Book Value
$0.64 per share

Miscellaneous

Free Float
24,679,000
Market Cap
$62.41 million
Optionable
Not Optionable
Beta
1.62
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Daniel Mark Bradbury (Age 63)
    Executive Chairman
    Comp: $158k
  • Mr. Bruce D. Steel C.F.A. (Age 58)
    Co-Founder, President, CEO & Director
    Comp: $796.95k
  • Ms. Christine Zedelmayer M.B.A. (Age 54)
    P.M.P., Senior VP & COO
    Comp: $561.75k
  • Dr. Stephen Connelly Ph.D. (Age 42)
    Chief Scientific Officer & Director
    Comp: $579.6k
  • Mr. Jason A. KeyesMr. Jason A. Keyes (Age 53)
    Chief Financial Officer
  • Mr. Michael Moore
    Vice President of Investor Relations & Corporate Communications
  • Dr. Matthew Ritter Ph.D.
    Senior Vice President of Corporate Development
  • Mr. Joel M. Rothman (Age 55)
    Chief Development Officer
  • Dr. Maple Fung M.D.
    Chief Medical Officer

EQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Equillium stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EQ shares.
View EQ analyst ratings
or view top-rated stocks.

What is Equillium's stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Equillium's shares. Their EQ share price targets range from $2.80 to $5.00. On average, they expect the company's stock price to reach $3.90 in the next year. This suggests a possible upside of 120.3% from the stock's current price.
View analysts price targets for EQ
or view top-rated stocks among Wall Street analysts.

How have EQ shares performed in 2024?

Equillium's stock was trading at $0.7230 at the start of the year. Since then, EQ shares have increased by 144.8% and is now trading at $1.77.
View the best growth stocks for 2024 here
.

When is Equillium's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EQ earnings forecast
.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.01. Equillium had a negative net margin of 36.96% and a negative trailing twelve-month return on equity of 51.82%.

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EQ) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners